Mucopolysaccharidoses are a group of metabolic disorders caused by the absence or malfunctioning of lysosomal enzymes needed to break down molecules called glycosaminoglycans. These long chains of sugar carbohydrates occur within the cells that help build bone, cartilage, tendons, corneas, skin and connective tissue. Glycosaminoglycans (formerly called mucopolysaccharides) are also found in the fluids that lubricate joints.
This report contains market size and forecasts of Mucopolysaccharidosis (MPS) Treatment in Global, including the following market information:
Global Mucopolysaccharidosis (MPS) Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Mucopolysaccharidosis (MPS) Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Stem Cell Therapies Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Mucopolysaccharidosis (MPS) Treatment include Sanofi, Shire (Takeda), BioMarin Pharmaceutical, Esteve, REGENXBIO Inc, Sangamo Therapeutics, Ultragenyx Pharmaceutical, Abeona Therapeutics and ArmaGen, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Mucopolysaccharidosis (MPS) Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Mucopolysaccharidosis (MPS) Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Mucopolysaccharidosis (MPS) Treatment Market Segment Percentages, by Type, 2021 (%)
Stem Cell Therapies
Enzyme Replacement Therapies
Global Mucopolysaccharidosis (MPS) Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Mucopolysaccharidosis (MPS) Treatment Market Segment Percentages, by Application, 2021 (%)
Hospitals
Clinics
Homecare
Global Mucopolysaccharidosis (MPS) Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Mucopolysaccharidosis (MPS) Treatment Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Mucopolysaccharidosis (MPS) Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Mucopolysaccharidosis (MPS) Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Sanofi
Shire (Takeda)
BioMarin Pharmaceutical
Esteve
REGENXBIO Inc
Sangamo Therapeutics
Ultragenyx Pharmaceutical
Abeona Therapeutics
ArmaGen
Eloxx Pharmaceuticals
Inventiva